Obesity Or Overweight With Type 2 Diabetes
RHHBYRoche HoldingCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Petrelintide (Amylin Analog) in Obesity Or Overweight With Type 2 Diabetes. The expected timing is based on the latest available company guidance and may change.
03/05/26:- ZUPREME-2 Ph2 monotherapy topline results expected in H2 2026. 05/06/26:- Petrelintide Ph2 showed 10.7% mean weight loss at week 42 with placebo-like tolerability and no vomiting. 07/23/26:- ZUPREME-2 topline results will be reported in H2 2026; combination trial will begin in coming months.
Verification
Confirm timing and program details against the company announcement or filing.